Investors > Analyst Reports

Analyst Reports

17-Dec-2024	CAR-NK-exosome in-vitro proof of concept for breast cancer

6-Dec-2024	Ovarian cancer biomarker validation

27-Aug-2024	FY24: Solid Progress; Exosome Therapeutics Key Program to Watch

21-Aug-2024	NEURO-NET validated for Parkinson's Disease EV isolation

9-Aug-2024	Ready to Fund Key FY25 Priorities

5-Jun-2024	Engineered Exosomes Kill Breast Cancer Cells In-vitro

7-May-2024	Leveraging Exosome Advantage

28-Feb-2024	SubB2M/CA15-3 test: beats leading breast cancer test by 19%

6-Nov-2023	1Q: Good cash runway as a new year of catalysts gets underway

7-Sep-2023	EXO-NET agreement with CDO to grow US revenue opportunity

7-Jul-2023	Global Joint Marketing Agreement: Major Boost to EXO-NET® Profile

28-Jun-2023	SubB2M/CA15-3 Test: Striking Study Results in Breast Cancer

13-Feb-2023	Good signs of progress in 2Q, SubB2M breast cancer study data

14-Dec-2022	OC97 study confirms EXO-NET utility for EV biomarker discovery

29-Nov-2022	EXO-NET kicks off in US; exosome work centralised in Melbourne

7-Nov-2022	MST Access: 1 1QFY23 closes with healthy cash balance

19-Oct-2022	MST Access: IIQ agrees to develop SubB2M test targeting pan-cancer diagnostic

25-Aug-2022	MST Access: Next-Gen Precision Diagnostics